文献速递瓣膜病与结构性心脏病

法国经导管主动脉瓣置换术时间趋势:从FRANCE 2到FRANCE TAVI

Temporal Trends in Transcatheter Aortic Valve Replacement in France: FRANCE 2 to FRANCE TAVI.
PubMed 文献 · J Am Coll Cardiol · 2017-01-01

该研究基于法国全国注册数据,比较FRANCE TAVI(2013–2015年,48中心,12,804例)与FRANCE 2(2010–2012年,34中心,4,165例)的TAVR表现趋势。FRANCE TAVI患者更年长但外科风险更低(中位logistic EuroSCORE 15.0% vs 18.4%),器械成功率从95.3%升至96.8%,院内和30天死亡率分别降至4.4%和5.4%。心脏压塞和起搏器植入率显著增加,而卒中及瓣环破裂/主动脉夹层保持稳定。

要点

  • TAVR患者趋向更年长但外科风险更低,经股入路占比超80%。
  • 器械成功率提高,院内和30天死亡率较前一时段显著下降。
  • 心脏压塞和起搏器植入率显著增加,需关注低外科风险患者扩展中的并发症。

核心结论

  • FRANCE TAVI注册显示全国范围内TAVR表现趋势令人安心,但鉴于适应证可能扩展至低外科风险患者,对潜在危及生命的并发症和起搏器植入的担忧仍然存在。

研究设计与样本

  • 前瞻性纳入2013年1月至2015年12月法国48个中心的TAVR患者(FRANCE TAVI注册,n=12,804),并与2010年1月至2012年1月34个中心的FRANCE 2注册(n=4,165)进行比较。

主要发现

  • FRANCE TAVI患者中位年龄84.6岁,男性占49.7%,中位logistic EuroSCORE为15.0%,低于FRANCE 2的18.4%(p<0.001)。
  • FRANCE TAVI中超过80%的患者接受经股动脉TAVR;经食管超声心动图引导从60.7%降至32.3%,杂交手术室使用从15.8%升至35.7%。
  • Valve Academic Research Consortium定义的器械成功率从FRANCE 2的95.3%升至FRANCE TAVI的96.8%(p<0.001)。
  • FRANCE TAVI的院内死亡率为4.4%、30天死亡率为5.4%,分别低于FRANCE 2的8.2%和10.1%(两者p<0.001)。
  • 卒中和潜在危及生命的并发症(如瓣环破裂或主动脉夹层)随时间保持稳定,而心脏压塞和起搏器植入率显著增加。

临床怎么用

  • 全国性注册数据支持TAVR在真实世界全人群中的实施趋势改善,器械成功率和短期生存提高。
  • 在向低外科风险患者扩展TAVR适应证时,应警惕心脏压塞和起搏器植入等并发症的增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Transcatheter aortic valve replacement (TAVR) is standard therapy for patients with severe aortic stenosis who are at high surgical risk. However, national data regarding procedural characteristics and clinical outcomes over time are limited. OBJECTIVES: The aim of this study was to assess nationwide performance trends and clinical outcomes of TAVR during a 6-year period. METHODS: TAVRs performed in 48 centers across France between January 2013 and December 2015 were prospectively included in the FRANCE TAVI (French Transcatheter Aortic Valve Implantation) registry. Findings were further compared with those reported from the FRANCE 2 (French Aortic National CoreValve and Edwards 2) registry, which captured all TAVRs performed from January 2010 to January 2012 across 34 centers. RESULTS: A total of 12,804 patients from FRANCE TAVI and 4,165 patients from FRANCE 2 were included in this analysis. The median age of patients was 84.6 years, and 49.7% were men. FRANCE TAVI participants were older but at lower surgical risk (median logistic European System for Cardiac Operative Risk Evaluation [EuroSCORE]: 15.0% vs. 18.4%; p < 0.001). More than 80% of patients in FRANCE TAVI underwent transfemoral TAVR. Transesophageal echocardiography guidance decreased from 60.7% to 32.3% of cases, whereas more recent procedures were increasingly performed in hybrid operating rooms (15.8% vs. 35.7%). Rates of Valve Academic Research Consortium-defined device success increased from 95.3% in FRANCE 2 to 96.8% in FRANCE TAVI (p < 0.001). In-hospital and 30-day mortality rates were 4.4% and 5.4%, respectively, in FRANCE TAVI compared with 8.2% and 10.1%, respectively, in FRANCE 2 (p < 0.001 for both). Stroke and potentially life-threatening complications, such as annulus rupture or aortic dissection, remained stable over time, whereas rates of cardiac tamponade and pacemaker implantation significantly increased. CONCLUSIONS: The FRANCE TAVI registry provided reassuring data regarding trends in TAVR performance in an all-comers population on a national scale. Nonetheless, given that TAVR indications are likely to expand to patients at lower surgical risk, concerns remain regarding potentially life-threatening complications and pacemaker implantation. (Registry of Aortic Valve Bioprostheses Established by Catheter [FRANCE TAVI]; NCT01777828).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Auffret V, Lefevre T, Van Belle E, et al. Temporal Trends in Transcatheter Aortic Valve Replacement in France: FRANCE 2 to FRANCE TAVI. J Am Coll Cardiol. 2017. PMID: 28662806. doi:10.1016/j.jacc.2017.04.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。